Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review - 05/11/20
, Peter Abdelmaseeh, MD a, Michael Megaly, MD, MS b, c, Richard Asinger, MD bAbstract |
The off-label use of direct oral anticoagulants (DOACs) for the treatment of left ventricular thrombi has grown over the past several years given the ease of administration, absence of a requirement for international normalized ratio (INR) monitoring, and freedom from dietary restrictions; however, the evidence for their safety and efficacy is contradictory. We systematically searched PubMed and Google Scholar from January 1, 2009, to April 25, 2020, for studies of DOACs for treatment of left ventricular thrombi. Fifty-three articles (of 1,168 patients) met our inclusion criteria. We found that the studies have reached conflicting results; based on our findings, their routine use for the treatment of left ventricular thrombi cannot be recommended. Adequately powered randomized controlled trials are needed to determine the safest and most effective treatment for left ventricular thrombi.
Le texte complet de cet article est disponible en PDF.Keywords : Direct oral anticoagulants (DOACs), Left ventricular thrombi
Plan
| Funding: None. |
|
| Conflicts of Interest: None. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 133 - N° 11
P. 1266 - novembre 2020 Retour au numéro
Article précédent
- Chagas Disease: Epidemiology and Barriers to Treatment
- Roger M. Mills
- Celestial Versus Terrestrial Travel—An Analysis of Spaceflight Fatalities and Comparison to Other Modes of Transportation
- Andrew S. Freiberg, Shouhao Zhou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?